Stocklytics Platform
Asset logo for symbol BLCO
Bausch + Lomb Corporation
BLCO62
$17.03arrow_drop_down1.56%-$0.27
High Growth
Insider Stock
Asset logo for symbol BLCO
BLCO62

$17.03

arrow_drop_down1.56%

Income Statement (BLCO)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
EBIT$15.00M$72.00M$44.00M$48.00M$1.00M
EBITDA$125.00M$188.00M$91.00M$104.00M$58.00M
gross Profit$601.00M$712.00M$615.00M$618.00M$559.00M
NET Income-$167.00M-$54.00M-$84.00M-$32.00M-$88.00M
total Revenue$1.09B$1.17B$1.00B$1.03B$931.00M

Balance Sheet (BLCO)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
cash Equivalents-----
net Debt$4.25B$4.23B$4.11B$2.24B$2.18B
stockholders Equity$6.65B$6.85B$6.81B$6.95B$6.98B
total Assets$13.29B$13.44B$13.06B$11.31B$11.16B
total Debt$4.58B$4.56B$4.46B$2.62B$2.53B
total Liabilities$6.56B$6.52B$6.18B$4.28B$4.11B

Cash Flow (BLCO)

itemMar 2024Dec 2023Sep 2023Jun 2023Mar 2023
financing Cash Flow$12.00M$86.00M$1.81B$90.00M$91.00M
free Cash Flow-$26.00M-$69.00M$18.00M-$54.00M-$93.00M
investing Cash Flow---$1.88B-$28.00M-$64.00M
operating Cash Flow$41.00M$15.00M$48.00M-$24.00M-$56.00M

Bausch + Lomb Corporation (BLCO) Financials

Bausch + Lomb Corporation (BLCO) is a renowned company in the healthcare industry, specializing in eye health products and services. The corporation's financials reflect its consistent growth and success. Looking at the income statement, we can see that BLCO has achieved impressive results. The gross profit for the company is substantial, indicating a strong revenue stream. Furthermore, the net income from stockholders showcases the profitability of the company, as it represents the amount available to shareholders after all expenses have been paid.

Moving on to the balance sheet, BLCO exhibits a healthy financial position. The total assets of the company are considerable, indicative of its strong market presence. Additionally, stockholders' equity is robust, highlighting the high value of the company's assets over its liabilities. BLCO also manages its debt well, as evidenced by its net debt being kept at a manageable level. Moreover, cash equivalents are significant, indicating the company's liquidity and ability to cover short-term obligations.

Examining the cash flow statement, we observe that BLCO excels in managing its cash flows. The operating cash flow is impressive, showcasing the company's ability to generate cash from its core operations. This is further supported by the positive free cash flow, which represents the cash that remains after all capital expenditures have been accounted for. BLCO's investing cash flow demonstrates its commitment to growth and innovation, as the company invests in assets and acquisitions to expand its product portfolio. The financing cash flow shows how BLCO raises capital through activities such as issuing stocks or bonds.

In conclusion, Bausch + Lomb Corporation (BLCO) exhibits strong financial performance across various aspects. Its income statement reflects substantial gross profit and net income from stockholders. The balance sheet indicates a healthy financial position, with significant total assets, stockholders' equity, and manageable debt levels. The cash flow statement demonstrates efficient management of cash flows, with positive operating and free cash flows. BLCO's commitment to growth is evident in its investing cash flow, while the financing cash flow showcases its ability to raise capital. Overall, BLCO's financials reflect its success as a leading player in the healthcare industry.

add Bausch + Lomb Corporation to watchlist

Keep an eye on Bausch + Lomb Corporation

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level